Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × pCR Rate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 410 Carcinoma, Non-Small-Cell Lung 283 Prostatic Neoplasms 202 Neoplasms 201 Neoplasm Metastasis 179 Melanoma 163 Multiple Myeloma 156 Colorectal Neoplasms 156 Leukemia, Myeloid, Acute 142 Lung Neoplasms 130 Leukemia 125 Lymphoma 118 Pancreatic Neoplasms 115 Recurrence 111 Leukemia, Lymphocytic, Chronic, B-Cell 110 Ovarian Neoplasms 109 Lymphoma, Non-Hodgkin 104 Carcinoma, Renal Cell 104 Brain Neoplasms 89 Myelodysplastic Syndromes 88 Precursor Cell Lymphoblastic Leukemia-Lymphoma 85 Glioblastoma 84 Lymphoma, Large B-Cell, Diffuse 80 Lymphoma, Follicular 78 Carcinoma, Hepatocellular 77 Head and Neck Neoplasms 76 Squamous Cell Carcinoma of Head and Neck 73 Urinary Bladder Neoplasms 64 Stomach Neoplasms 60 Hodgkin Disease 59

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡